Spectral Medical (TSE:EDT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Spectral Medical is pushing forward with its Tigris trial, enrolling 136 patients by the end of November despite supply chain disruptions caused by Hurricane Helene. The company expects to achieve full enrollment by the end of Q1 2025 and remains optimistic about overcoming these temporary setbacks.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.